MMP14 and cancer: The development of the mAb LEM-2/15, which targets the exposed loops of the catalytic domain of MT1-MMP with high affinity overcoming cross-reactivity with other MMP members, impairs ECM protein degradation and is a promising strategy to control MT1-MMP activity at the leading edge of migratory cancer cells since it has anti-angiogenic properties and reduced tumor cell invasion [118].